Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Phase III Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.

NCT06296212 is registered in ClinicalTrials.gov with Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica as lead sponsor.

NCT NCT06296212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06296212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Phase III Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.
Lead sponsor
Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica
Phase
Phase 3
Overall status
Unknown status
Start date
June 25, 2024
Completion date
September 30, 2025
Enrollment
178 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial injury, pneumonia